Nathan D. Pfeifer

541 total citations
14 papers, 409 citations indexed

About

Nathan D. Pfeifer is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Nathan D. Pfeifer has authored 14 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Pediatrics, Perinatology and Child Health and 4 papers in Pharmacology. Recurrent topics in Nathan D. Pfeifer's work include Drug Transport and Resistance Mechanisms (8 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Liver Disease Diagnosis and Treatment (3 papers). Nathan D. Pfeifer is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Pharmacological Effects and Toxicity Studies (3 papers) and Liver Disease Diagnosis and Treatment (3 papers). Nathan D. Pfeifer collaborates with scholars based in United States, United Kingdom and Germany. Nathan D. Pfeifer's co-authors include Kim L. R. Brouwer, Kyunghee Yang, Rhiannon N. Hardwick, Ana P. Lacerda, Robert Landewé, Alan Friedman, Gerd R Burmester, Mark C. Genovese, Kathleen Köck and Kevin B. Harris and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, The Annual Review of Pharmacology and Toxicology and Annals of the Rheumatic Diseases.

In The Last Decade

Nathan D. Pfeifer

14 papers receiving 404 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathan D. Pfeifer United States 10 251 141 113 69 52 14 409
Christopher Matheny United States 12 356 1.4× 122 0.9× 139 1.2× 32 0.5× 51 1.0× 23 695
Jason M. Gow United States 11 266 1.1× 103 0.7× 140 1.2× 40 0.6× 32 0.6× 12 615
Ulrike Gradhand Germany 8 369 1.5× 123 0.9× 176 1.6× 53 0.8× 11 0.2× 10 537
Varun Garg United States 11 174 0.7× 47 0.3× 50 0.4× 55 0.8× 50 1.0× 18 397
Woo‐Young Kim South Korea 14 217 0.9× 105 0.7× 88 0.8× 69 1.0× 29 0.6× 24 534
Florent Puisset France 13 215 0.9× 100 0.7× 58 0.5× 19 0.3× 54 1.0× 35 521
Fiora Bartoli Italy 12 154 0.6× 39 0.3× 108 1.0× 36 0.5× 23 0.4× 17 399
Katherine L. Gill United Kingdom 11 150 0.6× 154 1.1× 93 0.8× 25 0.4× 82 1.6× 15 446
Venkateswaran C. Pillai United States 12 151 0.6× 68 0.5× 62 0.5× 55 0.8× 28 0.5× 22 487
Ruth Lightfoot-Dunn United States 6 194 0.8× 182 1.3× 95 0.8× 54 0.8× 10 0.2× 9 341

Countries citing papers authored by Nathan D. Pfeifer

Since Specialization
Citations

This map shows the geographic impact of Nathan D. Pfeifer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan D. Pfeifer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan D. Pfeifer more than expected).

Fields of papers citing papers by Nathan D. Pfeifer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan D. Pfeifer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan D. Pfeifer. The network helps show where Nathan D. Pfeifer may publish in the future.

Co-authorship network of co-authors of Nathan D. Pfeifer

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan D. Pfeifer. A scholar is included among the top collaborators of Nathan D. Pfeifer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan D. Pfeifer. Nathan D. Pfeifer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Belperio, John A., Tuan S. Nguyen, David A. Lombardi, et al.. (2023). Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respiratory Research. 10(1). e001627–e001627. 5 indexed citations
2.
Abell, Thomas L., Braden Kuo, Tuba Esfandyari, et al.. (2023). A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. 35(4). e14523–e14523. 9 indexed citations
3.
Pfeifer, Nathan D., et al.. (2021). Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19. Clinical and Translational Science. 14(6). 2556–2565. 12 indexed citations
4.
5.
Burmester, Gerd R, Robert Landewé, Mark C. Genovese, et al.. (2016). Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 76(2). 414–417. 84 indexed citations
6.
Yang, Kyunghee, Nathan D. Pfeifer, Kathleen Köck, & Kim L. R. Brouwer. (2015). Species Differences in Hepatobiliary Disposition of Taurocholic Acid in Human and Rat Sandwich-Cultured Hepatocytes: Implications for Drug-Induced Liver Injury. Journal of Pharmacology and Experimental Therapeutics. 353(2). 415–423. 45 indexed citations
7.
8.
Pfeifer, Nathan D., Kyunghee Yang, & Kim L. R. Brouwer. (2013). Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition I: Characterization of Basolateral Versus Biliary Clearance Using a Novel Protocol in Sandwich-Cultured Hepatocytes. Journal of Pharmacology and Experimental Therapeutics. 347(3). 727–736. 81 indexed citations
9.
Pfeifer, Nathan D., Arlene S. Bridges, Brian C. Ferslew, Rhiannon N. Hardwick, & Kim L. R. Brouwer. (2013). Hepatic Basolateral Efflux Contributes Significantly to Rosuvastatin Disposition II: Characterization of Hepatic Elimination by Basolateral, Biliary, and Metabolic Clearance Pathways in Rat Isolated Perfused Liver. Journal of Pharmacology and Experimental Therapeutics. 347(3). 737–745. 28 indexed citations
10.
Pfeifer, Nathan D., Kevin B. Harris, Grace Yan, & Kim L. R. Brouwer. (2013). Determination of Intracellular Unbound Concentrations and Subcellular Localization of Drugs in Rat Sandwich-Cultured Hepatocytes Compared with Liver Tissue. Drug Metabolism and Disposition. 41(11). 1949–1956. 30 indexed citations
11.
Pfeifer, Nathan D., Rhiannon N. Hardwick, & Kim L. R. Brouwer. (2013). Role of Hepatic Efflux Transporters in Regulating Systemic and Hepatocyte Exposure to Xenobiotics. The Annual Review of Pharmacology and Toxicology. 54(1). 509–535. 55 indexed citations
12.
13.
Ji, Chengjie, William R. Tschantz, Nathan D. Pfeifer, Mohammed Ullah, & Nalini Sadagopan. (2011). Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Analytica Chimica Acta. 717. 67–76. 36 indexed citations
14.
Tschantz, William R., Nathan D. Pfeifer, Leyu Wang, et al.. (2007). Expression, purification and characterization of the human membrane transporter protein OATP2B1 from Sf9 insect cells. Protein Expression and Purification. 57(2). 163–171. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher Matheny Breakdown of academic impact, for papers by Jason M. Gow Breakdown of academic impact, for papers by Ulrike Gradhand Breakdown of academic impact, for papers by Varun Garg Breakdown of academic impact, for papers by Woo‐Young Kim Breakdown of academic impact, for papers by Florent Puisset Breakdown of academic impact, for papers by Fiora Bartoli Breakdown of academic impact, for papers by Katherine L. Gill Breakdown of academic impact, for papers by Venkateswaran C. Pillai Breakdown of academic impact, for papers by Ruth Lightfoot-Dunn
Rankless by CCL
2026